SMAD4 and neoplasm: Finally, we show that in HPV-positive cell lines SMAD4-loss sensitizes cells to DNA-damaging agents, such as cisplatin, suggesting that SMAD4-deficient HPV tumours may be preferentially susceptible to similar treatments.